Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both invitro and invivo

Ki Cheong Park, Seung Won Kim, Ji Hyun Park, Eun Hye Song, Jeong Won Yang, Hyun Joo Chung, Hye Jin Jung, Jinsuck Suh, Ho Jeong Kwon, Seung Hoon Choi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) is an attractive target for cancer therapy because it plays a key role in gene expression and carcinogenesis. N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) is a novel synthetic HDAC inhibitor (HDACI) that shows better pharmacological properties than a known HDACI present in the human fibrosarcoma cell: suberoylanilide hydroxamic acid (SAHA). Here, we investigate the anti-cancer activity of HNHA against breast cancer both in vitro and in vivo. HNHA arrested the cell cycle at the G1/S phase via p21 induction, which led to profound inhibition of cancer cell growth in vitro. In addition, HNHA-treated cells showed markedly decreased levels of VEGF and HIF-1α than SAHA and fumagillin (FUMA) when accompanied by increased histone acetylation. HNHA significantly inhibited tumor growth in an in vivo mouse xenograft model. HNHA-treated mice survived significantly longer than SAHA- and FUMA-treated mice. Dynamic MRI showed significantly decreased blood flow in the HNHA-treated mice, implying that HNHA inhibits tumor neovascularization. This finding was accompanied by marked reductions of proangiogenic factors and significant induction of angiogenesis inhibitors in tumor tissues. We have shown that HNHA is an effective anti-tumor agent in breast cancer cells in vitro and in breast cancer xenografts in vivo. Collectively, these findings indicate that HNHA may be a potent anti-cancer agent against breast cancer due to its multi-faceted inhibition of HDAC activity, as well as anti-angiogenesis activity.

Original languageEnglish
Pages (from-to)343-350
Number of pages8
JournalCancer Science
Volume102
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Histone Deacetylase Inhibitors
Breast Neoplasms
Neoplasms
Histone Deacetylases
Heterografts
Angiogenesis Inhibitors
Fibrosarcoma
G1 Phase
Acetylation
Growth
S Phase
Histones
Vascular Endothelial Growth Factor A
Cell Cycle
Carcinogenesis
Pharmacology
Gene Expression

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Ki Cheong ; Kim, Seung Won ; Park, Ji Hyun ; Song, Eun Hye ; Yang, Jeong Won ; Chung, Hyun Joo ; Jung, Hye Jin ; Suh, Jinsuck ; Kwon, Ho Jeong ; Choi, Seung Hoon. / Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both invitro and invivo. In: Cancer Science. 2011 ; Vol. 102, No. 2. pp. 343-350.
@article{db56def6eb1c4de0a7d0ce3950fa4b84,
title = "Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both invitro and invivo",
abstract = "Histone deacetylase (HDAC) is an attractive target for cancer therapy because it plays a key role in gene expression and carcinogenesis. N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) is a novel synthetic HDAC inhibitor (HDACI) that shows better pharmacological properties than a known HDACI present in the human fibrosarcoma cell: suberoylanilide hydroxamic acid (SAHA). Here, we investigate the anti-cancer activity of HNHA against breast cancer both in vitro and in vivo. HNHA arrested the cell cycle at the G1/S phase via p21 induction, which led to profound inhibition of cancer cell growth in vitro. In addition, HNHA-treated cells showed markedly decreased levels of VEGF and HIF-1α than SAHA and fumagillin (FUMA) when accompanied by increased histone acetylation. HNHA significantly inhibited tumor growth in an in vivo mouse xenograft model. HNHA-treated mice survived significantly longer than SAHA- and FUMA-treated mice. Dynamic MRI showed significantly decreased blood flow in the HNHA-treated mice, implying that HNHA inhibits tumor neovascularization. This finding was accompanied by marked reductions of proangiogenic factors and significant induction of angiogenesis inhibitors in tumor tissues. We have shown that HNHA is an effective anti-tumor agent in breast cancer cells in vitro and in breast cancer xenografts in vivo. Collectively, these findings indicate that HNHA may be a potent anti-cancer agent against breast cancer due to its multi-faceted inhibition of HDAC activity, as well as anti-angiogenesis activity.",
author = "Park, {Ki Cheong} and Kim, {Seung Won} and Park, {Ji Hyun} and Song, {Eun Hye} and Yang, {Jeong Won} and Chung, {Hyun Joo} and Jung, {Hye Jin} and Jinsuck Suh and Kwon, {Ho Jeong} and Choi, {Seung Hoon}",
year = "2011",
month = "2",
day = "1",
doi = "10.1111/j.1349-7006.2010.01798.x",
language = "English",
volume = "102",
pages = "343--350",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both invitro and invivo. / Park, Ki Cheong; Kim, Seung Won; Park, Ji Hyun; Song, Eun Hye; Yang, Jeong Won; Chung, Hyun Joo; Jung, Hye Jin; Suh, Jinsuck; Kwon, Ho Jeong; Choi, Seung Hoon.

In: Cancer Science, Vol. 102, No. 2, 01.02.2011, p. 343-350.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both invitro and invivo

AU - Park, Ki Cheong

AU - Kim, Seung Won

AU - Park, Ji Hyun

AU - Song, Eun Hye

AU - Yang, Jeong Won

AU - Chung, Hyun Joo

AU - Jung, Hye Jin

AU - Suh, Jinsuck

AU - Kwon, Ho Jeong

AU - Choi, Seung Hoon

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Histone deacetylase (HDAC) is an attractive target for cancer therapy because it plays a key role in gene expression and carcinogenesis. N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) is a novel synthetic HDAC inhibitor (HDACI) that shows better pharmacological properties than a known HDACI present in the human fibrosarcoma cell: suberoylanilide hydroxamic acid (SAHA). Here, we investigate the anti-cancer activity of HNHA against breast cancer both in vitro and in vivo. HNHA arrested the cell cycle at the G1/S phase via p21 induction, which led to profound inhibition of cancer cell growth in vitro. In addition, HNHA-treated cells showed markedly decreased levels of VEGF and HIF-1α than SAHA and fumagillin (FUMA) when accompanied by increased histone acetylation. HNHA significantly inhibited tumor growth in an in vivo mouse xenograft model. HNHA-treated mice survived significantly longer than SAHA- and FUMA-treated mice. Dynamic MRI showed significantly decreased blood flow in the HNHA-treated mice, implying that HNHA inhibits tumor neovascularization. This finding was accompanied by marked reductions of proangiogenic factors and significant induction of angiogenesis inhibitors in tumor tissues. We have shown that HNHA is an effective anti-tumor agent in breast cancer cells in vitro and in breast cancer xenografts in vivo. Collectively, these findings indicate that HNHA may be a potent anti-cancer agent against breast cancer due to its multi-faceted inhibition of HDAC activity, as well as anti-angiogenesis activity.

AB - Histone deacetylase (HDAC) is an attractive target for cancer therapy because it plays a key role in gene expression and carcinogenesis. N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) is a novel synthetic HDAC inhibitor (HDACI) that shows better pharmacological properties than a known HDACI present in the human fibrosarcoma cell: suberoylanilide hydroxamic acid (SAHA). Here, we investigate the anti-cancer activity of HNHA against breast cancer both in vitro and in vivo. HNHA arrested the cell cycle at the G1/S phase via p21 induction, which led to profound inhibition of cancer cell growth in vitro. In addition, HNHA-treated cells showed markedly decreased levels of VEGF and HIF-1α than SAHA and fumagillin (FUMA) when accompanied by increased histone acetylation. HNHA significantly inhibited tumor growth in an in vivo mouse xenograft model. HNHA-treated mice survived significantly longer than SAHA- and FUMA-treated mice. Dynamic MRI showed significantly decreased blood flow in the HNHA-treated mice, implying that HNHA inhibits tumor neovascularization. This finding was accompanied by marked reductions of proangiogenic factors and significant induction of angiogenesis inhibitors in tumor tissues. We have shown that HNHA is an effective anti-tumor agent in breast cancer cells in vitro and in breast cancer xenografts in vivo. Collectively, these findings indicate that HNHA may be a potent anti-cancer agent against breast cancer due to its multi-faceted inhibition of HDAC activity, as well as anti-angiogenesis activity.

UR - http://www.scopus.com/inward/record.url?scp=79952076504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952076504&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2010.01798.x

DO - 10.1111/j.1349-7006.2010.01798.x

M3 - Article

VL - 102

SP - 343

EP - 350

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -